Registry and biospecimen collection for synovial sarcoma patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to collect and store data and biological samples from patients diagnosed with synovial sarcoma to facilitate future research aimed at improving patient outcomes. Participants will provide access to their medical records, leftover tumor tissue, and may also give blood or saliva samples. They will complete questionnaires about their medical history and may be contacted periodically for updates over a span of up to 10 years. Genetic testing will be performed on the collected samples to explore potential insights into the disease.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Males or females of any age
2. Reported diagnosis of synovial sarcoma
3. Informed consent from subject (aged ≥18 years) or parent/guardian

Exclusion Criteria:

1. Individuals with sarcomas that do not fit the definition of those considered for this registry
2. Individuals who are unwilling to participate
3. Individuals who are unwilling or unable to provide written consent

Where it's running

• Children's Hospital of Philadelphia
  Philadelphia, Pennsylvania, United States Recruiting

Study contacts

• Principal investigator: Theodore Laetsch, MD — Children's Hospital of Philadelphia
• Study coordinator: Lauren Gutstein
• Email: gutsteinl1@chop.edu
• Phone: 267-425-2029

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• N-803 for progressive synovial sarcoma and myxoid/round cell liposarcoma after TCR-T therapy

  This trial tests whether N-803 can safely boost lingering TCR-T immune cells and help people whose synovial sarcoma or myxoid/round cell liposarcoma has progressed after prior TCR-T treatment.

  Recruiting Early Phase 1 Northwestern University · Chicago, Illinois · NCT07261657

• ACTengine IMA203 plus mRNA-4203 for cutaneous melanoma and synovial sarcoma

  This trial tests whether giving the ACTengine IMA203 T‑cell therapy together with the mRNA‑4203 vaccine is safe and helps people with HLA‑A*02:01 unresectable or metastatic cutaneous melanoma or synovial sarcoma who have had prior treatment.

  Recruiting at 4 sites Phase 1 Immatics US, Inc. · San Francisco, California and 3 other locations · NCT06946225

• Alpha/beta T‑Cell and B‑Cell Depletion plus Zoledronic Acid for Pediatric and Young Adult Solid Tumors

  This study will try removing alpha/beta T cells and B cells from donor stem cell grafts and giving zoledronic acid to see if it helps children and young adults (6 months to 25 years) with relapsed or high‑risk solid tumors tolerate allogeneic transplant and reduce relapse.

  Recruiting Phase 1/2 University of Florida · Gainesville, Florida · NCT06625190

• Using pasireotide to treat advanced synovial sarcoma and desmoplastic small round cell tumor

  This study is testing if the drug pasireotide can help young people with advanced synovial sarcoma and desmoplastic small round cell tumors stay healthy longer after their initial treatments.

  Recruiting Phase 2 University Hospital Heidelberg · Heidelberg, Baden-Wurttemberg and 3 other locations · NCT06456359

• MASCT-I plus doxorubicin and ifosfamide as first-line treatment for advanced soft tissue sarcoma

  This trial will test whether adding MASCT-I to standard chemotherapy (doxorubicin and ifosfamide) helps adults with advanced soft tissue sarcoma respond better or live longer.

  Recruiting Phase 2 HRYZ Biotech Co. · Guangzhou · NCT06277154

• Evaluating treatments for non-rhabdomyosarcoma soft tissue sarcoma in young patients

  This study is testing a combination of chemotherapy and radiation to see if it helps young patients with non-rhabdomyosarcoma soft tissue sarcoma live longer without their cancer coming back.

  Recruiting at 7 sites Phase 1/2 St. Jude Children's Research Hospital · Atlanta, Georgia and 6 other locations · NCT06239272

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.